Delving into the Latest Updates on ZS-802 with Synapse

Overview

Basic Info

Drug Type

AAV based gene therapy

Synonyms

Factor VIII-ZS802, 凝血因子Ⅷ-ZS802, ZS 802

+ [1]

Target

F8

Action

modulators

Mechanism

F8 modulators(Coagulation factor VIII modulators)

Therapeutic Areas

Congenital DisordersHemic and Lymphatic DiseasesOther Diseases

Active Indication

Hemophilia A

Inactive Indication-

Originator Organization

Sichuan Real & Best Biotech Co., Ltd.

Active Organization

Sichuan Real & Best Biotech Co., Ltd.

Inactive Organization-

Drug Highest PhasePhase 1/2

First Approval Date-

Regulation-

Login to view timeline

Primary objective: To evaluate the safety and tolerability of ZS802 injection in patients with severe hemophilia A. Secondary objective: To evaluate the pharmacokinetic (PK) and pharmacodynamic (PD) characteristics, immunogenicity, and efficacy of ZS802 injection in patients with severe hemophilia A.

Start Date14 Sep 2023

Sponsor / Collaborator

Sichuan Real & Best Biotech Co., Ltd.

NCT05523128

/ RecruitingNot ApplicableIIT

A Non-randomized, Open-label, Dose-escalation Study to Evaluate the Safety, Tolerability, Kinetics and Efficacy of a Single Intravenous Infusion of ZS802 in Hemophilia A Subjects With Endogenous FVIII ≤2%.

A non-randomized, open-label, dose-escalation study to evaluate the safety, tolerability, kinetics and efficacy of a single intravenous infusion of ZS802 in hemophilia A subjects with endogenous FVIII ≤2%.

Start Date29 Sep 2022

Sponsor / Collaborator

Hematology Hospital of Chinese Academy of Medical Sciences

100 Clinical Results associated with ZS-802

Login to view more data

100 Translational Medicine associated with ZS-802

Login to view more data

100 Patents (Medical) associated with ZS-802

Login to view more data

100 Deals associated with ZS-802

Login to view more data